Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4R? Antibody ATI-052
MWN-AI** Summary
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company, has announced the initiation of a Phase 1b proof-of-concept trial for its investigational bispecific antibody, ATI-052, aimed at treating asthma. The trial, which is placebo-controlled and randomized, will test the safety, tolerability, and efficacy of ATI-052 in approximately 16 patients who are currently on GINA steps 2-4 treatment. This trial follows a similar Phase 1b trial of ATI-052 that began for atopic dermatitis earlier this year, demonstrating Aclaris's commitment to advancing its pipeline of treatments for immuno-inflammatory diseases.
Dr. Jesse Hall, Aclaris's Chief Medical Officer, indicated that recent interim results from a Phase 1a trial of ATI-052 showed promising safety and pharmacokinetic profiles. The company plans to provide topline results from both the asthma and atopic dermatitis trials in the second half of 2026 and aims to subsequently launch a Phase 2b program for both indications.
ATI-052 is designed to simultaneously inhibit thymic stromal lymphopoietin (TSLP) and interleukin-4 receptor (IL-4R?), which are key players in inflammatory and allergic responses. The antibody's unique design provides it with potential best-in-class therapeutic properties. By targeting TSLP and IL-4R?, ATI-052 aims to address a range of atopic and respiratory diseases.
Aclaris holds exclusive worldwide rights to the antibody, excluding Greater China, and continues to leverage its robust R&D capabilities to develop drug candidates that meet the needs of patients with limited treatment options. This announcement reflects Aclaris's ongoing momentum and commitment to advancing innovations in the biopharmaceutical landscape.
MWN-AI** Analysis
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has recently made significant strides in its clinical development pipeline by initiating a Phase 1b proof-of-concept trial for ATI-052, a novel bispecific antibody targeting both thymic stromal lymphopoietin (TSLP) and interleukin-4 receptor (IL-4R) in asthma patients. This follows the earlier commencement of a similar trial for atopic dermatitis (AD), demonstrating Aclaris’ commitment to addressing unmet needs in immuno-inflammatory diseases.
Investors should view the initiation of this trial positively, particularly given the encouraging interim results from the Phase 1a trials that reported strong safety and tolerability profiles for ATI-052. The mechanism of action, which involves modulation of key inflammatory pathways, suggests that the drug could serve as a potential best-in-class treatment option, especially in patients not adequately served by existing therapies.
As the biotech sector heavily relies on clinical developments, Aclaris' ongoing trials may be critical in driving its stock price in the near term. The firm’s strategy to concurrently develop ATI-052 for both asthma and AD may enhance its chances of market success, while the expected top-line results in late 2026 could serve as pivotal catalysts for investor sentiment.
However, potential investors should approach with caution given the inherent risks involved in clinical trials, including regulatory hurdles and the variability of trial outcomes. Before making any investment decisions, it’s crucial for stakeholders to stay informed on trial progress and market conditions, as these will impact Aclaris' stock valuation significantly.
In conclusion, while Aclaris Therapeutics presents an intriguing investment opportunity with its promising pipeline, investors should remain vigilant about potential risks, implementing a wait-and-see approach until more definitive data emerges from the ongoing trials.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1b proof-of-concept (POC) trial of ATI-052, the Company’s potential best-in-class investigational bispecific anti-TSLP/IL-4R? antibody, in asthma. This announcement follows the recent initiation of the Company’s Phase 1b POC trial of ATI-052 in atopic dermatitis (AD). Planning is ongoing for a Phase 2b program encompassing asthma and atopic dermatitis as potential first indications. The Company expects to initiate this program in the second half of 2026.
“The start of 2026 has been a period of strong execution and momentum across our clinical programs, broadly, and with ATI-052 specifically,” said Dr. Jesse Hall, Chief Medical Officer of Aclaris. “The positive Phase 1a interim results for ATI-052 exceeded our expectations and demonstrated a strong safety and tolerability profile, extended pharmacokinetics, and concentration-dependent pharmacodynamics even at the lowest dose. Following the January announcement that we had initiated our POC trial in atopic dermatitis, we have now initiated our POC trial in asthma. We expect to provide top line results from both trials in the second half of 2026 and start the Phase 2b program shortly thereafter.”
The randomized (3:1), double-blind, placebo-controlled Phase 1b POC trial will evaluate the safety, tolerability, and efficacy of ATI-052 compared to placebo in approximately 16 patients with asthma on GINA (Global Initiative for Asthma) steps 2-4 treatment prior to screening. Endpoints that will be assessed include safety and tolerability parameters; pharmacokinetic parameters; respiratory pharmacodynamic (PD) biomarker assessments including FeNO (fractional exhaled nitric oxide); blood PD biomarker assessments including blood eosinophil count and endogenous cytokines/chemokines and inflammation markers in plasma/serum; and efficacy measures including FEV1.
Top line results from this trial and the ongoing Phase 1b POC trial in AD are expected in the second half of 2026.
About ATI-052
ATI-052 is an investigational humanized anti-TSLP and anti-IL-4R? bispecific antibody that simultaneously inhibits thymic stromal lymphopoietin (TSLP) and interleukin-4 receptor (IL-4R?) with high affinity and potency. By targeting TSLP, which sits at the top of the inflammatory cascade, it inhibits a broad range of inflammation; by targeting IL-4R?, it blocks downstream signaling of both IL-4 and IL-13, which are key cytokines involved in Th2-mediated inflammation and allergic diseases. ATI-052 exhibits potential best-in-class potency and utilizes the same TSLP antigen-binding fragment (Fab) region as the Company’s monoclonal antibody bosakitug (ATI-045), retaining the dissociation kinetics, long residence time, and high potency advantages over comparator antibodies, but is engineered to bind more tightly to the neonatal Fc receptor (FcRn) to extend its half-life. ATI-052 has the potential to treat a variety of atopic, immunologic and respiratory diseases. Aclaris has the exclusive worldwide rights to ATI-052, excluding Greater China.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations regarding its development plans for ATI-052, including the timing to report results from its Phase 1b trials of ATI-052 in AD and asthma, the timing to initiate a Phase 2b program including asthma and AD, the potential for ATI-052 to be a best-in-class anti-TSLP/IL-4R? bispecific monoclonal antibody, and the therapeutic potential for ATI-052 including in other atopic, immunologic and respiratory diseases. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, potential changes to interim, topline and preliminary data as more subject data become available, Aclaris’ reliance on third parties over which it may not always have full control, Aclaris’ ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the macroeconomic environment and other risks and uncertainties that are described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2024, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the “SEC Filings” page of the “Investors” section of Aclaris’ website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com
FAQ**
What are the key benchmarks that Aclaris Therapeutics Inc. ACRS expects to achieve in the upcoming Phase 2b program for ATI-052, specifically regarding the treatment of asthma and atopic dermatitis?
How does the safety and tolerability profile of ATI-052 compare to existing therapies currently available for asthma, as reported by Aclaris Therapeutics Inc. ACRS in the Phase 1b trial?
In what ways could the potential best-in-class designation of ATI-052, as claimed by Aclaris Therapeutics Inc. ACRS, impact its marketability and competitive positioning within the biopharmaceutical industry?
What are the anticipated risks and uncertainties Aclaris Therapeutics Inc. ACRS may face in the progression of clinical trials for ATI-052, and how could these affect investor confidence moving forward?
**MWN-AI FAQ is based on asking OpenAI questions about Aclaris Therapeutics Inc. (NASDAQ: ACRS).
NASDAQ: ACRS
ACRS Trading
-0.33% G/L:
$3.005 Last:
624,878 Volume:
$3.02 Open:
